BioCorRx Inc. (BICX)

[Pip611]

BioCorRx Retains MZ Group as Investor Relations Advisor

New PR firm means new investors! Let's get ready to run back to .30!


LOS ANGELES, CA--(Marketwired - Jul 20, 2016) - BioCorRx Inc. (OTC PINK: BICX) (the "Company"), developer of the BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program used in the treatment of alcohol and opioid addiction, announced today the Company has retained MZ Group as its investor relations advisor.
MZ will assist BioCorRx with communicating its corporate and financial developments to shareholders and investors, while establishing a strong public brand, expanding market coverage, and seeking to diversify the Company's investor base. Mike Cole, Senior Vice President for MZ North America, will be the Company's primary investor contact going forward and he and the MZ Group team will be advising the Company in all facets of corporate and financial communications.
"We chose to partner with MZ Group to expand and strengthen our investor relations efforts," said Brady Granier, CEO of BioCorRx. "We are accelerating our growth strategy to offer both our highly effective, proprietary program that is built around the use of the FDA-approved medication, naltrexone, while furthering our R&D initiatives to both expand and enhance our product offerings in the evolving market for addiction treatment. MZ Group provides the reach and established track record we need to develop relationships with a broad spectrum of investors who understand the potential of our implant delivery technology and treatment program."
"BioCorRx has developed a unique addiction treatment model that leverages a proprietary naltrexone based implant coupled with a treatment program to assist facilities across the country in helping addicts prepare for life without substance abuse," said Matt Hayden, Chairman of MZ Group North America. "After being surgically implanted by a medical professional, the naltrexone implant can significantly reduce cravings for alcohol or opioids for several months in some patients, depending on individual metabolism rates. By staying off alcohol and drugs, a person can get their mind clear and respond much better to counseling and rehabilitation as they get their life back on track. With a growing number of Americans seeking help in the $35 billion annual addiction treatment market, we believe BioCorRx offers a compelling solution and value proposition to its investors. We believe the Company's pursuit of FDA approval for its naltrexone-based implant also creates a path toward further market acceptance and penetration."

http://www.marketwired.com/press-release/biocorrx-retains-mz-group-as-investor-relations-advisor-otc-pink-bicx-2143987.htm